Abstract:

AIM: To explore the clinical effect of azithromycin combined with methylprednisolone in treating pulmonary consolidation from mycoplasma pneumonia. METHODS: Eighty-two patients with pulmonary consolidation from mycoplasma pneumonia were divided into control group and treatment group according to random number table method. The control group received routine treatment combined with azithromycin of 10 mg·kg^-1·d^-1 (intravenous drip,qd) and for a continuous treatment of 5 days. The treatment group received extra methylprednisolone of 1 mg/kg (intravenous drip,q12h) for a continuous treatment of 5 days on the basis of the control group. The clinical efficacy,clinical symptom relief time, the serum index and the adverse reaction occurred between two groups were compared. RESULTS: After treatment, the total effective rate in the treatment group and the control group was 90.24%(37/41) and 70.73%(29/41), respectively (P<0.05). The clinical symptom relief time in the treatment group was shorter than that of the control group (P<0.05). The C reactive protein (CRP) in the treatment group and the control group was (14.73±1.84) and (19.64±2.63)mg/L, interleukin-6 (IL-6) was (50.49±6.05) and (69.21±7.42) mg/L, erythrocyte sedimentation rate (ESR) was (27.47±3.30) and (31.11±4.73) mm/h,respectively (P<0.05). Both groups had rashes and itching, nausea and vomiting, and the adverse reaction rate in the treatment group and the control group was 26.83% (11/41) and 12.19% (5/41), respectively (P>0.05). CONCLUSION: The combined treatment of azithromycin plus methylprednisolone for pulmonary consolidation from mycoplasma pneumonia is better than azithromycin alone.It can effectively relieve clinical symptoms and improve clinical effect with no significant increase in the incidence of adverse drug reactions.

Key words: pulmonary consolidation from mycoplasma pneumonia, azithromycin, methylprednisolone, randomized controlled